Pascal Furet - Concepedia

Author

Pascal Furet

Novartis (Switzerland)

Also Known As

P. FURET, Pascal Furet

Publications

857

Citations

H-Index

Concepts

All Affiliations

Novartis (Switzerland)Novartis Institutes for BioMedical Research

About

Pascal Furet is an author at Novartis (Switzerland) specializing in pharmacology, drug discovery, and natural sciences.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	614
2	Natural Sciences	5	5	214
3	Biochemistry	3	3	159
4	Engineering	1	1	20
5	Biomolecular Engineering	1	1	21

Pascal Furet

Publications

809

Citations

H-Index

Page 1

	Year	Citations
Discovery of Asciminib (ABL001), an Allosteric Inhibitor of the Tyrosine Kinase Activity of BCR-ABL1 Joseph Schoepfer, Wolfgang Jahnke, Giuliano Berellini, Journal of Medicinal Chemistry Drug TargetMixed-phenotype Acute LeukemiaMolecular BiologyTumor BiologyMyeloid Neoplasia	2018	432
Total Synthesis and Biological Evaluation of the Nakijiquinones Petra Stahl, Lars Kissau, Ralph Mazitschek, Journal of the American Chemical Society Crystal StructureMedicinal ChemistryBioorganic ChemistryBiochemistryNatural Sciences	2001	113
Direct and selective pharmacological disruption of the YAP–TEAD interface by IAG933 inhibits Hippo-dependent and RAS–MAPK-altered cancers Emilie A. Chapeau, Laurent Sansregret, Giorgio Giacomo Galli, Nature Cancer	2024	104
Nonpeptidic angiotensin II antagonists: synthesis and in vitro activity of a series of novel naphthalene and tetrahydronaphthalene derivatives Peter Bühlmayer, Leoluca Criscione, Walter Fuhrer, Journal of Medicinal Chemistry	1991	36
New synthesis of oxcarbazepine via remote metalation of protected N-o-tolyl-anthranilamide derivatives Olivier Lohse, Ulrich Beutler, Peter C. Fünfschilling, Tetrahedron Letters Medicinal ChemistryNatural SciencesProtected N-o-tolyl-anthranilamide DerivativesChemical DerivativeOrganic Chemistry	2001	35
Abstract LB319: IAG933, a selective and orally efficacious YAP1/WWTR1(TAZ)-panTEAD protein-protein interaction inhibitor with pre-clinical activity in monotherapy and combinations Tobias Schmelzle, Emilie A. Chapeau, Daniel Bauer, Cancer Research PharmacotherapyAbstract Lb319ProteomicsRadiation OncologyNovel Therapy	2023	25
Optimization of Platelet-Derived Growth Factor Receptor (PDGFR) Inhibitors for Duration of Action, as an Inhaled Therapy for Lung Remodeling in Pulmonary Arterial Hypertension Duncan Shaw, Ferheen Baig, Ian Bruce, Journal of Medicinal Chemistry Pdgfr Kinase DomainPulmonary Arterial HypertensionPulmonary CirculationDrug DiscoveryPhysiology	2016	23
Optimization of a Class of Dihydrobenzofurane Analogs toward Orally Efficacious YAP‐TEAD Protein‐Protein Interaction Inhibitors Holger Sellner, Emilie A. Chapeau, Pascal Furet, ChemMedChem Drug TargetNanotherapeuticsPeptide SciencePharmacotherapyPharmaceutical Chemistry	2023	21
Ab initio studies of substituent effects on allene stability Pascal Furet, Robert L. Matcha, Richard Fuchs The Journal of Physical Chemistry Allene Stabilitypascal FuretEngineeringAltmetric Attention ScoreBibliometricsOrganic Chemistry	1986	20

Page 1